



Prascend[®]
(pergolide tablets)

MAKE THE MOST OF EVERY DAY

Help your horse thrive with
the No. 1 treatment approved by the
FDA for pituitary pars intermedia
dysfunction (PPID).

IMPORTANT SAFETY INFORMATION: PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

THE TRUSTED TREATMENT FOR PPID



PRASCEND® (pergolide tablets)
was the first treatment
approved by the FDA for PPID



Backed by more than 15 years
of use and extensive research



Proven to show improvement
in at least one clinical sign
within 180 days.¹



IMPORTANT SAFETY INFORMATION: PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

PPID SUCCESS STORY



RUSTY'S STORY: A PONY, A PARTNER, A PIONEER

More than 15 years ago, Rusty was diagnosed with PPID. He became part of the original clinical trial for PRASCEND® (pergolide tablets), and has received daily treatment ever since. Today, at an estimated 35 years old, Rusty is thriving — proving what's possible when horses with PPID stay on consistent, trusted treatment.

RUSTY HAS BEEN A GREAT FRIEND TO ME," HIS OWNER, MELISSA, SAID. "HE TAUGHT ME SO MUCH ABOUT HOW TO RIDE, AND HAS DONE THE SAME FOR MANY OF MY FRIENDS OVER THE YEARS."

IMPORTANT SAFETY INFORMATION: PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

PROVEN LONG-TERM RESULTS

Twenty-eight horses and two ponies — including Rusty — were monitored in a long-term study, designed to evaluate the lasting clinical impact of PRASCEND® (pergolide tablets).

100%
SHOWED SUSTAINED
CLINICAL IMPROVEMENT¹

87%
OF OWNERS SAID THEY WOULD TREAT
WITH PRASCEND TABLETS AGAIN¹

60%
ACHIEVED NORMAL
HORMONE LEVELS¹

IMPORTANT SAFETY INFORMATION: PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

PRASCEND® (PERGOLIDE TABLETS) VS. COMPOUNDED PERGOLIDE

While compounded pergolide may sometimes be used as an alternative to PRASCEND tablets, there are major concerns about its stability, potency and consistency.²

	 Prascend® (pergolide tablets)	Compounded Pergolide
CLINICAL EFFECTIVENESS STUDIES	✓ Required	✗ No
SAFETY STUDIES	✓ Required	✗ No
POTENCY STANDARDS	✓ Required	✗ No
ADVERSE-EVENT SURVEILLANCE AND REPORTING	✓ Required	Recommended but not required
GOOD MANUFACTURING PRACTICES/ STANDARDS	✓ Required	✗ No
FDA REVIEW OF LABELING, MARKETING AND PROMOTION	✓ Required	✗ No
DETAILED RECORDS OF EACH BATCH	✓ Required	✗ No

ASK YOUR VETERINARIAN ABOUT MANAGING PPIID WITH PRASCEND® (PERGOLIDE TABLETS)



SCAN TO LEARN MORE
AT PRASCEND.COM

IMPORTANT SAFETY INFORMATION: PRASCEND treatment may cause loss of appetite. Most cases are mild. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Not for human use. Do not ingest the product. Refer to the package insert for complete product information.

¹Schott HC, Strachota JR, Marteniuk JV, Refsal KR. Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide. *J Vet Intern Med* 2025;39(3):e370109. <https://doi.org/10.1111/jvim.70109>

²Stanley SD, DiMaio Knych HK. Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate, in *Proceedings*. 56th Annu Conv AAEP 2010;274–276. 2010:274–276

PRASCEND® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2025 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0407-2025